OncoMatch/Clinical Trials/NCT07261683
Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer
Is NCT07261683 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for ovarian cancer.
Treatment: Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron — The goal of this clinical trial is to learn if drug regimen weekly paclitaxel/nab-paclitaxel, pembrolizumab, and mirabegron works to treat relapsed ovarian cancer in adults. It will also learn about the safety of the drug regimen. The main questions it aims to answer are: i) Does drug weekly paclitaxel/nab-paclitaxel, pembrolizumab, and mirabegron reduce tumor volume? ii) What medical problems do participants have when taking drug weekly paclitaxel/nab-paclitaxel, pembrolizumab, and mirabegron? Participants will: i) Take drug paclitaxel/nab-paclitaxel every week and pembrolizumab every 21 days with everyday mirabegron ii) Visit the clinic once every 2 months for checkups and tests iii) Keep a diary of their symptoms
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — front line
Has received a front line platinum-based regimen ... with documented disease recurrence
Cannot have received: anti-PD-1/PD-L1/PD-L2 or co-inhibitory T-cell receptor therapy
Has received prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated antigen-4 [CTLA-4], tumor necrosis factor receptors OX-40 or CD137).
Cannot have received: systemic anticancer therapy
Exception: allowed if completed >4 weeks before enrollment
Has received prior systemic anticancer therapy including radiation therapy or maintenance therapy within 4 weeks before enrollment.
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
Has adequate organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify